Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology

American Cancer Society. Facts and Figures, 2005. Atlanta: ACS; 2005:2.

American Cancer Society. Facts and Figures, 2005. Atlanta: ACS; 2005:2. )| false
• Search Google Scholar
• Export Citation

American Cancer Society. Facts and Figures, 2005. Atlanta: ACS; 2005:3.

American Cancer Society. Facts and Figures, 2005. Atlanta: ACS; 2005:3. )| false
• Search Google Scholar
• Export Citation

Status of the medical oncology workforce. The American Society of Clinical Oncology. J Clin Oncol 1996;14:2612–2621.

Status of the medical oncology workforce. The American Society of Clinical Oncology. J Clin Oncol 1996;14:2612–2621. )| false
• Search Google Scholar
• Export Citation

NCCN Drug Compendium. Available at: http://www.nccn.org/professionals/drug_compendium/Content/contents.asp?button=I+Agree. Accessed November 2005.

NCCN Drug Compendium. Available at: http://www.nccn.org/professionals/drug_compendium/Content/contents.asp?button=I+Agree. Accessed November 2005. )| false
• Search Google Scholar
• Export Citation

H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173. Enacted December 8, 2003. Available at: http://www.cms.hhs.gov/mmu/HR1/PL108-173summary.asp. Accessed November 2005.

H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173. Enacted December 8, 2003. Available at: http://www.cms.hhs.gov/mmu/HR1/PL108-173summary.asp. Accessed November 2005. )| false
• Search Google Scholar
• Export Citation

Dunning D, Paivanas TA. Proprietary client database. Accessed July 1, 2005.

DunningDPaivanasTA. Proprietary client database. Accessed July 1, 2005. )| false
• Search Google Scholar
• Export Citation

Oncology Business Management issues in the Changing Reimbursement Environment. 2005 American Society of Clinical Oncology (ASCO) meeting. Available at: http://www.asco.org/ac/1,1003,_12-002673-00_18-0034-00_19-00921-00_29-00E,00.asp.

Oncology Business Management issues in the Changing Reimbursement Environment. 2005 American Society of Clinical Oncology (ASCO) meeting. Available at: http://www.asco.org/ac/1,1003,_12-002673-00_18-0034-00_19-00921-00_29-00E,00.asp. )| false
• Search Google Scholar
• Export Citation

Omnibus Budget Reconciliation Act (OBRA) of 1989 added section 1848(c)(2)(B)(1) to the Social Security Act. Requires that CMS reviews all work relative value units (RVUs) – physician work, practice expense and malpractice insurance- for services in Medicare's Resource Based Relative Value Scale (RBRVS) physician fee schedule (MFS) no less often than every five years.

Omnibus Budget Reconciliation Act (OBRA) of 1989 added section 1848(c)(2)(B)(1) to the Social Security Act. Requires that CMS reviews all work relative value units (RVUs) – physician work, practice expense and malpractice insurance- for services in Medicare's Resource Based Relative Value Scale (RBRVS) physician fee schedule (MFS) no less often than every five years. )| false
• Search Google Scholar
• Export Citation

American Medical Association. Current Procedural Terminology (CPT®). Available at: http://www.ama-assn.org/ama/pub/category/3113.html. Accessed November 2005.

American Medical Association. Current Procedural Terminology (CPT®). Available at: http://www.ama-assn.org/ama/pub/category/3113.html. Accessed November 2005. )| false
• Search Google Scholar
• Export Citation

Langer CJ, Leighton JC, Comis RL et al.. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860–1870.

LangerCJLeightonJCComisRL. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860–1870. )| false
• Search Google Scholar
• Export Citation

Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309–318.

GoldenbergMM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309–318. )| false
• Search Google Scholar
• Export Citation

Coiffier B, Lepage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242.

CoiffierBLepageEBriereJ. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242. )| false
• Search Google Scholar
• Export Citation

Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997;15:744–749.

AbrattRPBezwodaWRGoedhalsLHackingDJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997;15:744–749. )| false
• Search Google Scholar
• Export Citation

Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001;6(suppl 3):26–29.

BaselgaJTaberneroJM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001;6(suppl 3):26–29. )| false
• Search Google Scholar
• Export Citation

Czuczman MS, Koryzna A, Mohr A et al.. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694–704.

CzuczmanMSKoryznaAMohrA. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694–704. )| false
• Search Google Scholar
• Export Citation

Fisher B, Brown AM, Dimitrov NV et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.

FisherBBrownAMDimitrovNV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496. )| false
• Search Google Scholar
• Export Citation

De Gramont A, Banzi M, Navarro M et al.. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial [abstract]. Proc Am Soc Clin Oncol 2003;22:253. Abstract 1015.

De GramontABanziMNavarroM. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial [abstract]. Proc Am Soc Clin Oncol 2003;22:253. Abstract 1015. )| false
• Search Google Scholar
• Export Citation

Tabernero J, Butts C, Cassidy J et al.. Capecitabine and oxaliplatin in combination (Xelox) as first-line therapy for patients with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial [abstract]. Proc Am Soc Clin Oncol 2002;21:133a. Abstract 531.

TaberneroJButtsCCassidyJ. Capecitabine and oxaliplatin in combination (Xelox) as first-line therapy for patients with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial [abstract]. Proc Am Soc Clin Oncol 2002;21:133a. Abstract 531. )| false
• Search Google Scholar
• Export Citation

Blum JL, Savin MA, Edelman G et al.. Abraxane Q3W- Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract]. Pro Am Soc Clin Oncol 2004;22(suppl 14). Abstract 543.

BlumJLSavinMAEdelmanG. Abraxane Q3W- Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract]. Pro Am Soc Clin Oncol 2004;22(suppl 14). Abstract 543. )| false
• Search Google Scholar
• Export Citation

Physician fee schedule final rule published in the Federal Register on November 15,2004 (page 66308) announcing one-year demonstration project associated with caring for cancer patients receiving chemotherapy services in an office-based practice for calendar year (CY 2005).

ASCO Lawyer Review's CMS's New Interim G-Codes. Oncol News Int 2005;14;75–76.

ASCO Lawyer Review's CMS's New Interim G-Codes. Oncol News Int 2005;14;75–76. )| false
• Search Google Scholar
• Export Citation

Section 1848(d)(1)(E) of the Social Security Act requires the Secretary to make an estimate of the Sustainable Growth Rate (SGR) and conversion factor applicable to Medicare Payments for physician services, published in the 11/1/2005 Federal Register and effective 1/1/2006.

Centers for Medicaid and Medicare Services. Recommendations Regarding Supplemental Practice Expense Data Submitted for 2003. Evaluation of Survey Data for: Physical Therapy, Oncology, Cardiology, Pediatrics. Available at: fhttp://www.cms.hhs.gov/physicians/pfs/PErecommendations2003.pdf. Accessed November 2005.

Centers for Medicaid and Medicare Services. Recommendations Regarding Supplemental Practice Expense Data Submitted for 2003. Evaluation of Survey Data for: Physical Therapy, Oncology, Cardiology, Pediatrics. Available at: fhttp://www.cms.hhs.gov/physicians/pfs/PErecommendations2003.pdf. Accessed November 2005. )| false
• Search Google Scholar
• Export Citation